## SANTA CRUZ BIOTECHNOLOGY, INC.

# BRMS1L (E-18): sc-241931



#### BACKGROUND

BRMS1L (breast cancer metastasis-suppressor 1-like) is a 323 amino acid protein that localizes to the nucleus and exists as a component of the mSin3A/ HDAC1 (histone deacetylase) complex. Sharing similarity with BRMS1, BRMS1L is involved in HDAC1-dependent transcriptional repression and, in lung cancer tissue, functions to inhibit cell growth, suggesting a role in tumor suppression. The gene encoding BRMS1L maps to human chromosome 14, which houses over 700 genes and comprises nearly 3.5% of the human genome. Chromosome 14 encodes the presinilin 1 (PSEN1) gene, which is one of the three key genes associated with the development of Alzheimer's disease (AD). The SER-PINA1 gene is also located on chromosome 14 and, when defective, leads to the genetic disorder  $\alpha$ 1-antitrypsin deficiency, which is characterized by severe lung complications and liver dysfunction.

### REFERENCES

- Kuzmichev, A., Zhang, Y., Erdjument-Bromage, H., Tempst, P. and Reinberg, D. 2002. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1). Mol. Cell. Biol. 22: 835-848.
- Nikolaev, A.Y., Papanikolaou, N.A., Li, M., Qin, J. and Gu, W. 2004. Identification of a novel BRMS1-homologue protein p40 as a component of the mSin3A/p33(ING1b)/HDAC1 deacetylase complex. Biochem. Biophys. Res. Commun. 323: 1216-1222.
- Meehan, W.J., Samant, R.S., Hopper, J.E., Carrozza, M.J., Shevde, L.A., Workman, J.L., Eckert, K.A., Verderame, M.F. and Welch, D.R. 2004. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J. Biol. Chem. 279: 1562-1569.
- Albani, D., Roiter, I., Artuso, V., Batelli, S., Prato, F., Pesaresi, M., Galimberti, D., Scarpini, E., Bruni. A., Franceschi, M., Piras, M.R., Confaloni, A. and Forloni, G. 2007. Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. Neurobiol. Aging 28: 1682-1688.
- 5. Cruz, P.E., Mueller, C. and Flotte, T.R. 2007. The promise of gene therapy for the treatment of  $\alpha$ -1 antitrypsin deficiency. Pharmacogenomics 8: 1191-1198.
- Filley, C.M., Rollins, Y.D., Anderson, C.A., Arciniegas, D.B., Howard, K.L., Murrell, J.R., Boyer, P.J., Kleinschmidt-DeMasters, B.K. and Ghetti, B. 2007. The genetics of very early onset Alzheimer disease. Cogn. Behav. Neurol. 20: 149-156.
- Martín-Subero, J.I., Ibbotson, R., Klapper, W., Michaux, L., Callet-Bauchu, E., Berger, F., Calasanz, M.J., De Wolf-Peeters, C., Dyer, M.J., Felman, P., Gardiner, A., Gascoyne, R.D., Gesk, S., Harder, L., Horsman, D.E., Kneba, M., Küppers, R., Majid, A., Parry-Jones, N., Ritgen, M., et al. 2007. A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. Leukemia 21: 1532-1544.

#### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

#### CHROMOSOMAL LOCATION

Genetic locus: BRMS1L (human) mapping to 14q13.2; Brms1I (mouse) mapping to 12 C1.

## SOURCE

BRMS1L (E-18) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of BRMS1L of human origin.

## PRODUCT

Each vial contains 200  $\mu g$  IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-241931 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

### **APPLICATIONS**

BRMS1L (E-18) is recommended for detection of BRMS1L of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with BRMS1.

BRMS1L (E-18) is also recommended for detection of BRMS1L in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for BRMS1L siRNA (h): sc-92226, BRMS1L siRNA (m): sc-141748, BRMS1L shRNA Plasmid (h): sc-92226-SH, BRMS1L shRNA Plasmid (m): sc-141748-SH, BRMS1L shRNA (h) Lentiviral Particles: sc-92226-V and BRMS1L shRNA (m) Lentiviral Particles: sc-141748-V.

#### **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.